Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
Novo Nordisk's experimental drug results in up to 24% weight loss
07:35pm, Friday, 20'th Jun 2025
Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company rea
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
07:34pm, Friday, 20'th Jun 2025
Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full resu
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
03:45pm, Friday, 20'th Jun 2025
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (June 2025)
10:40am, Friday, 20'th Jun 2025
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo
Why Novo Nordisk (NVO) is a Great Dividend Stock Right Now
12:46pm, Wednesday, 18'th Jun 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
11:56am, Wednesday, 18'th Jun 2025
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
U.S. judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
11:05am, Wednesday, 18'th Jun 2025
A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge br
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
10:51am, Wednesday, 18'th Jun 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 18'th Jun 2025
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?
07:45am, Wednesday, 18'th Jun 2025
It wasn't so long ago that Novo Nordisk (NVO -3.44%), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders. However, the past year has been challenging for the drugmaker.
Why Novo Nordisk Stock Sank by Nearly 4% Today
06:21pm, Monday, 16'th Jun 2025
Novo Nordisk (NVO -3.50%) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company. A price target cut from an analyst tracking the company only e
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
01:36pm, Monday, 16'th Jun 2025
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
07:04am, Monday, 16'th Jun 2025
You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk.
Novo Nordisk: The Strength To Withstand Challenges
04:29am, Monday, 16'th Jun 2025
Novo Nordisk's price has regained momentum in recent weeks after seeing a big slump earlier in 2025. With strong financials, and robust profit estimates even after a downgrade in outlook, NVO could co
